like ivig-focus reposit initi
neutral due month wait poc data
momenta transform complex gener biosimilar litig
magnet convent pipeline-focus biotechnolog compani
like see believ focu ivig market provid
least four way stock work importantli ivig market involv
complex analyt valid core momenta
probabl access compani final legaci complex
gener busi provid annual off-set pipelin cost
neonat twice isnt charm certain blood-typ mismatch
parent lead profound complic second later
pregnanc mother sensit previou pregnanc momenta
anti-fcrn mab tight bind properti allow
tight control danger anti-fet antibodi pregnant mother
ivig off-label juggernaut ivig bulk antibodi isol plasma
activ gener off-label astonish number diseas state
although replac singl molecul therapeut mani indic
current usag larg billion shortag common
momenta second third pipelin therapeut essenti ivig
mimic design effici replac plasma-deriv bulk ivig
old black magic momenta complex legaci busi left
compani on-going revenu stream annual
biosimilar unit humira eylea biosimilar hope
launch said biosimilar arena becom increasingli
complex low visibl potenti launch
explicitli model time
base autoimmun condit neonat use
assum discount rate termin growth rate
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
initi coverag momenta pharmaceut inc neutral
rate although think new direct extrem promis good match
momenta analyt focu see key poc data least year away
stock isnt truli cheap billion market cap compani transform
convent biotech focu antibodi relat diseas four
main clinic program seem relat enough allow synergi develop
potenti commerci addit program seem focus larg
maternal-fet immun relat toxic base antibodi
high-affin near complet coverag fcrn receptor
autoimmun indic program clearli behind competitor
market larg mani potenti specif indic
possibl monthli dose
ivig-tr indic classic momenta approach involv
analyt character ivig find fraction antibodi
actual anti-diseas properti creat improv therapi
fraction term hypersialyl ivig somewher cog sold
play improv therapeut approach program seem lowest risk
safeti readout larg key hurdl
ivig-rel therapi therapeut like target
specif indic rather broad-ivig replac strategi
expect rel fast act
maternal-fet indic repres fresh direct crowd field
major valu ascrib momenta pipelin base treatment
maternal-fet autoimmun diseas condit similar profil matern
antibodi cross develop fetu caus damag momenta approach
group diseas hdfn largest least eight start
diseas result matern deriv antibodi caus fetal anemia
specif danger antibodi known subsequ compani explor
opportun block fetal effect matern autoimmun diseas
myasthenia gravi lupu
hdfn complex landscap need signific across treatment
landscap center excel babi develop anemia week
gestat term gestat age ga mortal rate
initi test popul clinic trial measur fraction babi
deliv healthi week ga poc data expect treat
babi alway add complex clinic trial hdfn seem ideal routin non-
invas dna test identifi risk mother non-invas ultrasound test identifi
anem babi final exist soc extrem poor ivig current use
despit efficaci data suggest therapi lengthen safe pregnanc day
first mg trial set stage futur develop clear momenta style
compani first trial autoimmun indic design flush dose
respons curv igg reduct function dose mg well suit
type detail examin quantit role pathogen antibodi tightli
correl diseas sever affin may allow igg reduct never
achiev five-arm trial enrol patient idea serv dose
springboard move trial multipl indic
exhibit mg use defin dose-efficaci respons
albumin-a-go-go side death grip substrat on-target
effect human albumin level date reduct albumin rang
seen clinic consequ issu bear watch believ
modest edema last sever month probabl accept mother
high-risk pregnanc itp patient look lifetim therapi
babi result think neonat applic may natur match
competit fcrn modul space crowd competit seem fierc
momenta significantli behind belgian antibodi powerhous argenx argx
rate develop fcrn blocker result diseas like mg momenta
may need better order signific commerci futur addit mani
target diseas treatabl rituxan potenti b-cell
deplet antibodi anti-b-cel therapi near patent expiri mani
locat make commerci roll-out fcrn modul therapi complex
gene therapi miss piec gene therapi develop essenti
everi corner drug develop land scape howev correct disease-
caus gene via aav-bas gene therapi highli immunogen result
immun memori respons essenti remov chanc second applic
dose modif result dose one shot estim condit young
peopl run risk wane efficaci effective-dos requir chang
patient growth addit aav vector encount fraction patient
preexist antibodi specif aav capsid may candid
therapi gener although still plan stage
unpatrol abil reduc igg might allow gene-therapi window
enzym replac therapi may benefit window beyond intern
program believ abil improv current futur
exampl revolut enzym
replac therapi ert pioneer genzym divis sanofi sni
rate transkaryot therapeut part shire shpg rate
certainli chang live mani patient howev potenti immun
reject ert remain on-going issu least diseas includ
pomp diseas abil avoid ert reject major determin factor
patient expect lifespan similarli fcrn modul origin develop
help hemophilia patient inhibitor factor ada although field chang
rapidli role may still emerg drug like
ivig opportun space-ag program ivig mixtur igg
antibodi pool thousand donor deliv patient on-label
use includ replac therapi sever immunocompromis acut infect
patient amount billion market perhap interest second
market size billion base abil ivig help patient
vari autoimmun conditionsprob condit
mechan ivig action condit often unknown probabl differ
differ diseas part effort move beyond complex gener
innov medicin momenta initi two program design mimic use
ivig better defin molecul case momenta approach
abil grow unmet ivig need result chronic shortag
plasma-deriv antibodi also superior product least term deliveri
side effect
hsivig program program predic publish data suggest
increas sialyl increas affin ivig inhibitori fcriib receptor
hypersialyl indic increas incorpor common cell surfac sugar
group antibodi molecul process chang activ antibodi
biolog assay half-lif antibodi organ momenta present
support pre-clin data program includ increas specif
activ replac ivig convent ivig assay mimet activ
fraction ivig seem like rel de-risk approach address
continu shortag ivig also potenti yield therapeut superior
user-friendli product
gener copaxon biosimilar durabl momenta two legaci busi
direct includ gener copaxon million annual profit
momenta profit split sandoz biosimilar unit humira
eylea biosimilar hope launch opportun dwarf
novel therapeut pipelin believ could help off-set burn enough
matter biosimilar arena becom increasingli complex low visibl
potenti launch explicitli model time
risk invest thesi
develop risk despit enthusiasm potenti applic
great thing date seen rel littl human data addit fcrn
modul field crowd potenti rais bar commerci viabl product
product deem posit risk-reward profil fda
regulatori risk risk signific momenta stori therapeut aim
high-risk pregnanc bound attract fda scrutini momenta seem
address issu initi focus high-risk pregnanc
infant mortal approach big factor momenta stori mani
product compani develop expect new regul
therefor take longer approv like encount delay
note momenta spent lot time educ fda familiar probabl
reduc risk remain import stori
competit risk sever compani addit momenta current
develop anti-fcrn agent includ argenx mutat fc fragment mg
itp argx rate ucb pharma mab complet itp mg
ucbji rate immunov adcc mutant alexion plan
mg rate affibodi monomer z/albumin-bind domain fusion
exhibit multipl on-going fcrn modul effort
momenta point sever area differenti mab-lik fragment
develop includ fulli human high affin antibodi block
fc bind site rather compet fc site aglycosyl
sugar effector function import properti therapeut
expect given high dose argument seem compel detail
clinic trial import
exhibit import competit belgian llama-palooza
momenta pharmaceut princip develop stage therapeut compani
signific revenu stream annual next sever year stem
prior focu develop complex gener current focu improv
treatment larg number diseas state respond often via unclear
mechan bulk intraven immunoglobulin ivig momenta approach
ivig replac refin use compani hard-won expertis precis
analysi modif complex macromolecul mixtur compani
develop four import pipelin program gener immunomodul
maternal-fet immun relat toxic base antibodi
high-affin near complet coverag fcrn receptor
autoimmun indic program behind competitor
market larg possibl monthli dose
ivig-tr indic classic momenta approach involv
analyt character ivig find fraction antibodi
actual anti-diseas properti creat improv therapi
fraction term hypersialyl ivig somewher cog play
improv therapeut approach program seem lowest risk
safeti readout larg key hurdl
ivig-rel therapi therapeut like target
specif indic rather broad-ivig replac strategi
expect rel fast act
momenta pipelin fulli de-risk time-frame
certain product itp could gener import data time
exhibit momenta pipelin product candid
deriv valuat per share use dcf analysi assum
discount rate termin growth rate feel appropri
reflect collect potenti uncertainti associ momenta early-stag
pipelin name termin growth rate seem fair success momenta
much ivig space expect compani continu innov
refin first set product discount rate reflect lack human data
program increas actual cost capit promis compani like
model revenu gener hdfn mg itp
risk-adjust basi respect net present valu npv
analysi peak sale hdfn mg itp estim
cash posit discount back demonstr valuat predominantli
driven itp per share hdfn per share cash
per share mg per share momenta legaci complex gener
explicitli model lead program full knowledg
success program could open door addit maternal-fet
condit anoth autoimmun indic captur potenti hsivig
indic entri essenti mimic growth itp delay
two year
valuat captur sale base ip assumpt although
compani provid signific detail know anapti
rate ipo made antibodi com patent around make sens
momenta comment new patent base specif enzym use
hypersialyl ivig consist protect least anoth year possibl
hdfn
assum probabl success
assum approxim million million women
eu respect childbear age percent expect give
birth given year child later
estim condit probabl least two k-/k pregnanc
assum gener popul k-
estim price per pregnanc high risk hdfn
grow annual rate price seem justifi base avoid
per day bed lifelong complic hdfn infant
assum market entri peak penetr increment
increas year thereaft loe
assum flat royalti rate ex-u sale
assum gross margin sale
exhibit hdfn market model
hdfn market marketwomen childbear growth given fertil child child k-/k pregnanc condit probabl least two k-/k address prophylaxis- penetration- per pregnancy- growth- hdfn revenu momenta mm marketwomen childbear growth given fertil child child k-/k pregnanc condit probabl least two k-/k address prophylaxis- penetration- per pregnancy- growth- hdfn revenu momenta mm royalti momenta- hdfn revenu momenta mm
mg
assum probabl success
assum preval mg approxim grow
annual rate respect
assum mg case consid gener mg
refractori standard care
estim price per patient per year grow
annual rate
assum market entri peak penetr increment
increas year thereaft loe lower penetr base
competit natur mg come decad includ expect
argenx may get market year momenta
assum flat royalti rate ex-u sale
assum gross margin sale
exhibit mg market model
mg market marketmg gener mg refractori refractori treat penetration- per patient per year- growth- mg revenu momenta marketmg gener mg refractori refractori treat penetration- per patient per year- growth- mg revenu momenta royalti momenta- mg revenu momenta
itp
assum probabl success
assum preval itp grow annual
rate respect
assum itp case consid primari itp
requir use steroid primari itp refractori steroid
estim price per patient per year par
plasmapheresi grow annual rate
assum market entri peak penetr increment
increas year thereaft loe
assum flat royalti rate ex-u sale
assum gross margin sale
exhibit itp market model
itp market marketitp itp primari itp requir primari itp requir itp refractori steroid primari itp refractori treat itp- penetration- treat addit indications- penetration- per patient per year- growth- itp revenu momenta marketitp itp primari itp requir primari itp requir itp refractori steroid primari itp refractori treat penetration- treat addit indications- penetration- per patient per year- growth- itp revenu momenta royalti momenta itp revenu momenta
modul fcrn combat igg relat diseas
fcrn cellular receptor respons select transfer across membran igg
antibodi albumin transfer process result
increas half-lif antibodi rel protein
exchang antibodi mother develop fetu
momenta sever compani develop inhibitor fcrn design
stimul igg clearanc therapeut approach combat igg relat diseas
myasthenia gravi lupu maternal-fet igg-rel toxic sever
import aspect overal therapeut approach eventu commerci
winner specif diseas may depend detail therapeut antibodi
approach gener non-specif reduct diseas caus
antibodi come expens reduct total igg antibodi
appropri level igg reduct like vari diseas
serum albumin hsa human also stabil fcrn receptor
modul therapeut potenti lead concomit reduct igg
albumin differ level
cellular qualiti control everyth cell turn fairli rapid clip probabl
ensur cellular integr highli reactiv environ protein
turnov non-specif extracellular milieu constantli taken small
membran bound vesicl pinocytosi content non-specif degrad
lysosom
exhibit antibodi unusu long half-lif vivo
secret antibodi stabil unlik cellular protein antibodi
unusu long vivo lifetim reason antibodi stabil
circul subject degrad part time fact much time
antibodi protect within cell vesicl cellular receptor mediat
protect traffick term fcrn impli name fcrn first recogn
neonat transport matern igg mother milk across intestin
barrier blood rat importantli momenta stori fcrn also
transport igg across placenta final fcrn act transport igg across
epitheli endotheli barrier enhanc igg-medi antigen present
dendrit cell along increas vivo half-lif igg structur fcrn
receptor famili class receptor display intracellular
peptid t-cell howev fcrn mutat away peptid
display function use face molecul bind fc region
antibodi albumin
ph switch key featur interact fcrn igg albumin
bind fcrn ph-depend manner bind acid ph
releas neutral ph properti essenti fcrn rescu igg albumin
lysosom degrad overal cycl involv non-specif uptak cell
follow acidif uptak vesicl term endosom insid cell
acid environ trigger bind igg via fc fragment fcrn follow
exocytosi cell surfac exposur blood neutral ph result
releas igg protein bind fcrn deliv lysosom
momenta fcrn modul candid
optim high affin bind fcrn anti-fcrn antibodi
momenta got somat hypermut rate
sparingli anapti product unusu high affin activ
human nhp great advantag preclin test
ph resist bind bind picomolar affin fcrn endosom ph
extracellular ph allow occup fcrn throughout
engin effectorless design without effector shown promis avoid
could otherwis contribut dlt possibl stifl develop altogeth
low effector function higher dose nevertheless remain issu
epitop specif igg bind data date suggest appear
broad immunosuppress prevent igg product respons antigen
stimul effect igg synthesis/catabol effect igm iga ige
collect translat well clinic increas incid sever
infect data far
clinic develop
fcrn work mani therapeut categori momenta develop along
sever line includ mediat antibody-rel diseas
myasthenia gravi mg preclin develop human mg like play
unusu role develop diseas well-defin relationship
igg level diseas symptom provid good test case defin dose-
igg respons curv toward end momenta begun rel
extens trial five dose arm said commerci mg may less
import develop diseas may requir high bind
properti fcrn potenti long-term treatment reduct
level might actual neg addit consider behind fcrn
strong associ igg level diseas sever addit signific
commerci opportun mg seem ideal test case high affin
key question reduc igg level beyond achiev way
matter advantag efficaci balanc actual even perceiv risk due
concomit reduct albumin word fcrn inhibitor argenx
like approv compel risk reward dont
know think mg good indic answer question
myasthenia gravi antibody-medi diseas affect neuromuscular
junction diagnos mg gener case involv antibodi
recogn acetylcholin receptor achr detect lead
degrad postsynapt achr activ complement
remain mg patient lack detect anti-achr antibodi present
isotyp antibodi muscle-specif tyrosin kinas musk also produc
alter neuromuscular junction
exhibit defin relationship igg lower gmg efficaci score
mg gener diagnos base clinic often doubl vision droop eyelid
electrophysiolog serolog featur standard treatment mg involv
corticosteroid patient unabl toler steroid refractori treatment
broad-bas immunosuppress cyclosporin methotrex
tacrolimu use drug exhaust mg patient
tertiari referr clinic exhibit refractori diseas
refractori patient ivig plasma exchang plex use acut
exacerb mainten therapi final thymectomi demonstr
control trial non-thymomat gener achr mg
like condit test rituximab use chimer
mab bind fc domain recruit immun effector cell caus b-
cell lysi result rituximab produc substanti reduct circul b-cell
month drug wide use b-cell cancer dlbcl fl cll see
modest use ra
exhibit mg develop timelin
hemolyt diseas fetu newborn hdfn hdfn rare alloimmun
condit lead substanti morbid mortal condit develop
igg molecul produc mother pass placenta via neonat fc
receptor fcrn caus destruct rbc fetu newborn mild hdfn
often asymptomat worst caus mild jaundic manag
phototherapi howev sever hdfn often lead enlarg liver/spleen/heart cardiac
decompens and/or hydrop extrem swell eventu caus perinat
death left untreat current rh prevent form hdfn
would repres approxim birth rho-d immunoglobulin rhogam
wide use prevent alloimmun sinc introduct rho-d
immunoglobulin rhogam prevent product matern rho-d antibodi
sever decad ago incid anti-d hdn decreas substanti
recogn remain signific unmet need non-rh hdfn subtyp name
royal colleg obstetrician gynaecologist
anti-d hdfn associ hemolysi matur rbc anti-kel
hdfn associ decreas level prematur red blood cell reticulocyt
turn lead elev bilirubin by-product death anti-k hdfn predominantli
promot immun system-medi destruct progenitor caus
sever hdfn regardless titer anti-kel suppress bone marrow activ inhibit
erythroid progenitor cell anti-kel hdfn second common caus
sever hemolyt diseas newborn diseas behind anti-d hdfn anti-kel
becom rel import prevent diseas also becom
effect popul kell neg kell posit
proactiv matern antibodi screen help curb growth incid
hdfn manag complic continu repres disproportion share
prenat neonat care burden requir frequent antenat monitor
sometim iut exchang transfus typic requir case associ
sever anemia and/or sever hyperbilirubinemia sinc blood product use
exchang transfus highli restrict donor continu remain short
suppli contenti sourc strain healthcar system
highlight neonat receiv repeat iut significantli alter
neonat trajectori effect fetal hb first intrauterin transfus
shortest-liv continu presenc residu antibody-co fetal
rbc subsequ intrauterin transfus fetal hemopoiesi process produc
rbc suppress fetal circul maintain compat
transfus rbc suscept hemolyt process result late
anemia neonat common haemopoiet suppress induc
intrauterin transfus program may last mani week deliveri
exhibit iut outcom still leav much desir
neonat fc receptor fcrn direct transfer matern immunoglobulin igg
antibodi across placenta provid fetu newborn passiv
protect humor immun accordingli anti-fcrn mab like momenta may
therapeut role manag case anti-d anti-k hdfn competit
bind fcrn may abl prevent matern fetal transfer pathogen
igg prevent hdfn alloimmun alreadi occur ex vivo studi
recent demonstr compel inhibit igg transfer matern fetal
circul minim transfer see exhibit
exhibit hdfn propos moa
exhibit prevent igg transfer ex placenta model
momenta initi poc clinic trial hdfn per
clinicaltri gov studi plan enrol pregnant women high risk earli onset
sever hdfn efficaci measur proport patient live birth
gestat age week without iut secondari endpoint includ gestat age
first fetal iut frequenc fetal iut postnat manag phototherapi
exchang transfus transfus within first three month life pd/pk
measur mg/kg weekli momenta aim demonstr full fcrn occup
reduct igg baselin top-line data expect
exhibit hdfn poc trial design
spoke kol role fcrn modul hdfn left
hdfn consid high-risk pregnanc case close monitor
led believ transient reduct albumin well-docu
would easili identifi manag therefor might substanti
concern physician
rh outcom current achiev rhogam satisfactori displac
role prevent rh alloimmun novel therapeut agent would
like difficult
on-label use antibodi replac therapi
ivig new sandbox momenta analyt muscl
ivig mixtur igg antibodi pool thousand donor deliv
sever
immunocompromis patient fairli straightforward less million
market perhap interest abil ivig help patient vari
autoimmun condit exact mechan action mainli unknown
probabl differ differ diseas later group indic commerci
signific probabl grow mostli treat off-label overal sale ivig
world-wide top billion exhibit valu improv ivig prepar
mimet shown quit clearli sale tpo agonist attempt improv
patient platelet count stimul platelet product rather inhibit
destruct sale nplate promactin expect exceed billion
therefor momenta could garner fraction market would signific
view
exhibit ivig busi act via larg famili igg receptor
unfortun suppli ivig often constrain hamper development
expans effort also shortcom plasma-deriv ivig includ
possibl impur well signific variat immunoglobulin iga contenta
potenti concern due allergi part effort move beyond complex
gener arena innov medicin momenta initi work three
separ program area case momenta program face fair bit
competit similar program compani
exhibit preval diseas ivig commonli administ
hsivig program predic somewhat controversi notion
increas sialyl term hypersialyl increas incorpor common
cell surfac sugar group increas affin ivig inhibitori fcriib receptor
uniqu igg receptor trigger activ inhibitor immun system function
term itim program seem least interest us underli biolog
univers accept seem modif ivig would help
problem current ivig beyond reduc suppli constraint due potenti higher
rel activ prepar momenta present interest data
program includ abil prepar improv appear
mous ear fairli clear plan partner program
exhibit hypersialyl ivig increas activ
itp first man studi momenta choos initi clinic
indic allow quantit dose-respons readout much like case mg
momenta hope use first trial itp igg-medi bleed diseas
see understand dose-respons rel ivig itp also true
commerci opportun momenta target commerci launch
itp bleed disord character igg recognit platelet key driver
coagul process leav platelet cover antibodi term
opson unnatur state mimic antibodi attack pathogen
subsequ igg bind platelet destroy fc-mediat adcc cdcc
platelet therapeut efficaci ivig itp like base simpli swamp
system introduct mani fc region one per antibodi gram
ivig immun cell never actual find opson platelet remark
crude platelet haystack defens seem work ivig still broadli use itp
despit develop specif therapeut said ivig work well
itp respons rate respons also rapid featur much
basi test itp high bar least efficaci lower
conveni equival compel
itp big market itp affect patient incid
patient patient well control avail medic
chronic itp affect patient major risk itp
bleed event event lead hospit averag cost
control outpati set averag cost
result therapeut send patient home potenti valuabl
exhibit approv brand treatment consensu sale
like autoimmun diseas corticosteroid treatment howev patient
take steroid long period without signific side effect includ weight
gain diabet complic infect risk result ivig often use
applic dose ivig activ itp huge gram per kg
gram averag adult dose requir multi-day infus lead
common occurr headach rarer occurr catastroph side effect
includ kidney failur ivig rescu effect nearli time respons
short week
sever recombin therapeut approv ipd includ nplate
thrombopoietin receptor agonist tpo-ra increas platelet product
megakaryocyt tpo-ra show initi respons rate high longer-
term respons rang addit fostamatinib oral inhibitor
test two trial yield stabl respons patient
fostamatinib vs placebo drug defin ae profil includ
alt increas splenectomi also later line therapi itp prolong respons
report rang
broad applic sialyl addit drive fc receptor interact hyper-
sialyl sugar residu decor natur cellular protein n-and o-
link glycan prevent bind scaveng receptor liver cell
receptor involv natur turnov protein also respons
bind receptor momenta bag new trick might employ increas
half-lif mani cellular protein
defin ivig mimet momenta second program ivig replac
use defin fc complex design bind fc receptor specif geometri
avoid activ refer fc receptor famili cell surfac protein
immun cell bind antibodi fc region gener antibodi found
target fc-bind event gener activ immun cell two
except activ paradigm relev biotechnolog industri
fcriib receptor inhibit immun cell function receptor
exploit buy pt produc anti-immun therapeut
fcrn receptor discuss bind fc receptor ph-depend
cycl allow anti-bodi intern stabil maternal-fet
program seem like compet program time would
expect two approach ivig replac might equival everi
mimic igg-dim sub-fract ivig work modul
immun respons fc region ivig realli matter exampl indic
exhibit left specif activ ivig purifi fc region essenti
ident preclin model addit more-subtl immuno-modulatori
mechan ivig mediat igg mixtur dimer
multimer result bind one igg receptor immun cell
mechanist believ simultan bind pull igg receptor
receptor raft less activ tri mimic phenomenon momenta
experi differ form stabl fc multim effici modul
immun respons result winner trimer structur standard fc
scaffold present two addit fc domain exhibit right solut difficult
explain detail mechanist point view exhaust approach seem
reason eye howev given non-natur final structur consid
approach higher risk hsivig program safeti lack
immunogen need shown clinic studi
exhibit optim fc multim
partnership earli momenta partner program
compani plasma blood protein space deal includ million up-front
variou opt-in provis momenta fulli opt partner
fund develop commerci cost exchang
profit royalti ex-u
geometri may compet momenta may face competitor arena
gliknik privat compani whose lead molecul partner
rate say may program silent rather trimer igg fc
molecul gliknik test higher order multim fc fragment lot
visibl multim momenta test base patent gliknik
test larg number multim linear polym
ghost momenta past glatopa biosimilar
glatopa littl engin didnt glatopa brand name given momenta
gener copaxon drug use front-lin treatment multipl sclerosi copaxon
extrem complex mixtur peptid one time look like
great growth engin momenta stori copaxon chemic name glatiram
acet administ subcutan mg/ml formul deliv qd
mg/ml formul deliv sale glatopa book partner sandoz
nv rate momenta receiv profit share incom momenta
current million annual seem unlik grow buy
pt also market gener form see teva teva neutral
continu fight hold market share age cash cow
exhibit glatopa a-b rate gener copaxon
multipl sclerosi ms autoimmun inflammatori diseas central nervou
system character neuron demyelin progress axon injuri
subsequ death first clinic present ms gener neurolog
impair last day term first clinic demyelin event fcde
clinic isol syndrom ci fdce often occur optic nerv spinal cord
due eas detect cerebr lesion may common
clinic silent later lesion increasingli detect brain mri ms
incur patient gener begin treatment diagnosi copaxon gener
first line drug due favor safeti profil trial copaxon reduc
annual relaps rate rate period intens diseas activ prior
introduct gener copaxon peak sale billion
irregulatori histori momenta work commerci glatopa sandoz
april glatopa mg/ml approv fda approv came teva
mg formul copaxon approv teva success
convert patient conveni formul bundl rebat
momenta formul use api seem languish fda
fill/finish partner receiv fda warn letter freez approv clock
glatopa mg final approv earli nearli six month version
mg mg drug approv
biosimilar like anoth disappoint stori approxim billion sale
biolog expect risk due approv biosimilar product
next year base opportun momenta enter biosimilar area
idea analyt prowess would allow creat higher qualiti product
might easier time declar interchang origin biolog
end hurdl interchang low patent estat around
origin product proven robust anticip result
opportun look much less interest current momenta
complet clinic develop humira biosimilar hope enter
market find commerci partner base larg non-disclos
agreement rate momenta expect enter humira
market eu market
exhibit eylea attract biosimilar target
second biosimilar version eylea develop dme trial initi
vegf-receptor fusion protein expect approach billion ww sale
time biosimilar entri
research safer antibodi ert eat beyond gout
addit applic may abil dose patient protein
therapeut develop anti-drug antibodi ada applic
would like make sens case therapeut lifesav
overcom ada extrem expens exampl given
essenti everi protein therapeut potenti attract immun system
attent result anti-drug antibodi ada respons reduc
efficaci use treatment durat mani therapeut exampl includ switch
tnf-binder treat ibd similarli hemophilia develop
inhibitor recombin clot factor exampl ada forc patient
undergo process induc toler induct de-sensit immun
system factor order re-establish efficaci refer cost
million million like success half time mani
patient undergo one attempt final immun reaction life-
threaten diseas pomp diseas lethal glycogen storag disord
case develop inhibitori antibodi enzym replac therapi
ert major determin patient life expect result pomp
patient physician go extrem measur includ use anti-tumor drug
rituxan power immunosuppress get patient accept low level
gene therapi intern program partner opportun
gene therapi unleash nearli scienc fiction success treatment
patient via gene therapi second decad success area princip
involv ex vivo engin cell treat sever immun defici area
success probabl hint reason approach use
broadli introduc gene patient lack gene like highli
immunogen addit newli introduc gene product introduc gene
therapi second strongli immunogen player gene therapi arsen
viral vector current employ introduc gene mammalian cell also highli
immunogen laboratori approach caus problem howev
vivo recogn destroy natur gene deliveri engin raison
detr immun system
approxim patient found natur immun mani viral vector
unabl benefit even singl administr gene therapi
preexist antibodi particular problem adenoviru vector
repeat dose also possibl addit patient cant receiv
singl dose gene therapi patient cant receiv repeat dose concur
second issu seem one import hurdl gene therapi svp-
rapamycin might address briefli first administr viru patient
b-cell gener antibodi elimin viru initi respons take
day mount often provid window viral gene therapi vector infect
target tissu transfect gene interest howev immun system
quick studi subsequ infect viru encount rapid immun
respons due presenc memori b-cell result subsequ infus
viru elimin bodi within hour limit abil effect
affect target tissu
exhibit aav vector use tissu tropism
engin aav vector creat immunolog new variant describ
patient might benefit specif gene therapi
expect anti-vir antibodi vector creat applic
current patient exclud clinic trial lock gene
therapi revolut selecta aim tackl problem use synthet viral
vector synthet aav result analyz rule aav virion assembl
use structur mani natur virion come common origin
basi studi determin evolutionari ancestor aav vector
somewhat surpris theoret ancestor viru easi manufactur
function gene deliveri vehicl import featur selecta
viru ever truli exist calcul ancestor archeolog find
long long time ago current human immun system would expect
memori overal goal use vector current immun
respons exist along svp-rapamycin block immun
respons develop
thoma shrader harrison incom statementu itp- mg- hdfn- complex collabor total expensescogs- sg total oper incom interest incom expens loss dispos assetsoth expenseincom incom tax non- net incom non- ep total adjust net incom ep basic share dilut share
thoma shrader harrison balanc sheetu cash market collabor prepaid expens current total current market properti equip restrict intang total account accru accru collabor defer total current defer total common stock addit paid-in accumul comprehens accumul treasuri total stockhold total liabil stockhold
thoma shrader harrison statementu incom impair stock-bas amort premium amort loss dispos chang oper asset liabilitiescollabor prepaid expens current restrict long-term account accru accru collabor defer leas current long-term net cash use oper purchas properti proce dispos purchas market proce matur market net cash use invest proce public offer common stock net issuanc net proce issuanc common proce issuanc common stock stock repurchas common stock pursuant share surrender- net cash use financ net decreas cash cash cash equival begin cash equival end
btig cover compani mention report
appendix analyst certif import disclosur
